May 9th, MGI received 2 broad based patents covering the compound MGI 114, the lead analog in the companies acylfulvene family of anti cancer compounds currently in Phase I human clinical trial.
The acylfulvenes potentially offer a unique theraputic advance in treating solid tumor types; lung, colon, breast, skin and others that are resistant to other forms of chemotherapy.
They currently sell Salegen, which helps people who don't salivate after radiation therapy to the head and neck area. They make a profit with Salegen, and additional approval for other dry mouth applications are in the works. Dry mouth seems silly, but it really causes great health problems when it is chronic.
They currently have no debt, but they aren't making a profit.
Jim Adams is the contact at MGI (612) 935-7335. I talked to him today and he was very helpful. I'm not technically able to answer many questions, but I do have the annual report and will do my best.
I'd appreciate any comments.
Mark Oliver |
